Laboratory Studies

See the list below:

Molecular genetic testing^{[19, 20]}- Routine diagnostic testing for spinal muscular atrophy (SMA) involves targeted mutation analysis to detect deletion of exons 7 and 8 of SMN1. Approximately 95-98% of individuals with a clinical diagnosis of SMA lack exon 7 in both copies of SMN1 (ie, they are homozygous for the deletion). Approximately 2-5% of individuals with a clinical diagnosis of SMA are compound heterozygotes for deletion of SMN1 exon 7 and an intragenic mutation of SMN1. Routine genetic testing detects only patients with the homozygous deletion. However, additional testing is available that includes SMN1 sequence analysis for the detection of point mutations in the SMN1 gene. Genetic testing has also been developed that uses the quantitative polymerase chain reaction to determine the SMN2 gene copy number; however, such testing is not yet widely available. The SMN2 gene copy number is variable, rangingfrom0-5.
Other testing - Serum creatine kinase levels may be elevated but usually not to the extent that they are elevated in persons with muscular dystrophy. Serum aldolase levels also are commonly elevated in persons with types III and IV SMA.

Imaging Studies

See the list below:

Ultrasonographic imaging of the muscles has been used to assess for neurogenic atrophy in spinal muscular atrophy (SMA), but it is fairly nonspecific. Ultrasonography has lost favor as a diagnostic tool for SMA. Neuroimaging of patients with SMA reveals no brain abnormalities.

Other Tests

See the list below:

Muscle biopsy reveals evidence of neurogenic atrophy and chronic reinnervation in spinal muscular atrophy (SMA). Skeletal muscle changes include atrophy with a combination of narrow fibers and large, hypertrophic fibers. These fibers are separated by abundant fat and fibrous tissues. Increase in the sarcolemmal nuclei with preservation of striations is observed. The phrenic (C3-C5) and sacral (S2-S4) sphincter motor neurons are spared. Typical findings consistent with neurogenic atrophy also are seen on biopsy and are discussed above in the Pathophysiology section.
Electromyography (EMG) and nerve conduction studies (NCS) can be very useful for the physician in the diagnosis of SMA. Diffuse abnormalities on EMG are seen in the extremities and bulbar musculature. The findings are consistent with axonal degeneration. Fibrillation potentials, positive sharp waves, and complex, repetitive discharges are common. Large motor unit potentials are typical, but small amplitudes also have been seen. Upon recruitment, polyphasic motor unit potentials, decreased recruitment, fast firing, and synchronization of motor units are seen. A marked increase in jitter on electromyograms often is seen and helps to differentiate SMA types III and IV from ALS. Motor nerve conduction velocities are normal or slightly decreased. Motor unit action potentials (MUAPs) progressively decrease in amplitude. Sensory nerve action potentials (SNAPs) are normal.

Treatment & Management

Bradley WG, ed. Neurology in Clinical Practice. 5th ed. Philadelphia, Pa: Butterworth-Heinemann/Elsevier; 2008.
Herring JA, ed. Tachdjian's Pediatric Orthopaedics. 4th ed. Philadelphia, Pa: Saunders/Elsevier; 2008.
Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007 Aug. 22(8):1027-49. [QxMD MEDLINE Link].
Russman BS, Buncher CR, White M, et al. Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology. 1996 Oct. 47(4):973-6. [QxMD MEDLINE Link].
Moosa A, Dubowitz V. Spinal muscular atrophy in childhood. Two clues to clinical diagnosis. Arch Dis Child. 1973 May. 48(5):386-8. [QxMD MEDLINE Link]. [Full Text].
Umphred DA, ed. Neurological Rehabilitation. 5th ed. St Louis, Mo: Mosby Elsevier; 2007.
Merlini L, Granata C, Bonfiglioli S, et al. Scoliosis in spinal muscular atrophy: natural history and management. Dev Med Child Neurol. 1989 Aug. 31(4):501-8. [QxMD MEDLINE Link].
Querin G, El Mendili MM, Lenglet T, et al. The spinal and cerebral profile of adult spinal-muscular atrophy: a multimodal imaging study. Neuroimage Clin. 2018 Nov 28. [QxMD MEDLINE Link].
Zerres K, Rudnik-Schöneborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997 Feb 27. 146(1):67-72. [QxMD MEDLINE Link].
Ioos C, Leclair-Richard D, Mrad S, et al. Respiratory capacity course in patients with infantile spinal muscular atrophy. Chest. 2004 Sep. 126(3):831-7. [QxMD MEDLINE Link]. [Full Text].
Lin LC, Jong YJ. Pulmonary function assessment in patients with spinal muscular atrophy type II and type III. Acta Paediatr Taiwan. 2004 Jan-Feb. 45(1):15-8. [QxMD MEDLINE Link].
Muscular Dystrophy Campaign sponsored workshop: recommendation for respiratory care of children with SMA type II and III. Neuromuscular Disord. 2003. 13:184-189.
Viguier A, Lauwers-Cances V, Cintas P, et al. Spinal muscular atrophy with respiratory distress type 1: a multicenter retrospective study. Neuromuscul Disord. 2018 Oct 31. [QxMD MEDLINE Link].
Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet J Rare Dis. 2017 Apr 11. 12 (1):67. [QxMD MEDLINE Link]. [Full Text].
Souza PVS, Pinto WBVR, Ricarte A, et al. Clinical and radiological profile of patients with spinal muscular atrophy type 4. Eur J Neurol. 2021 Feb. 28 (2):609-19. [QxMD MEDLINE Link].
Simic G. Pathogenesis of proximal autosomal recessive spinal muscular atrophy. Acta Neuropathol. 2008 Jul 16. [QxMD MEDLINE Link].
Mattis VB, Bowerman M, Kothary R, et al. A SMNDelta7 read-through product confers functionality to the SMNDelta7 protein. Neurosci Lett. 2008 Jun 26. [QxMD MEDLINE Link].
Sedghi M, Behnam M, Fazel E, et al. Genotype-phenotype correlation of survival motor neuron and neuronal apoptosis inhibitory protein genes in spinal muscular atrophy patients from Iran. Adv Biomed Res. 2014. 3:74. [QxMD MEDLINE Link]. [Full Text].
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet. 2002 Dec. 111(6):477-500. [QxMD MEDLINE Link].
Wang CC, Chang JG, Ferrance J, et al. Quantification of SMN1 and SMN2 genes by capillary electrophoresis for diagnosis of spinal muscular atrophy. Electrophoresis. 2008 Jul. 29(13):2904-11. [QxMD MEDLINE Link].
Madsen KL, Hansen RS, Preisler N, Thogersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle Nerve. 2015 Aug. 52 (2):240-4. [QxMD MEDLINE Link].
Rodillo E, Marini ML, Heckmatt JZ, et al. Scoliosis in spinal muscular atrophy: review of 63 cases. J Child Neurol. 1989 Apr. 4(2):118-23. [QxMD MEDLINE Link].
Trucco F, Ridout D, Scoto M, et al. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology. 2021 Jan 26. 96 (4):e587-99. [QxMD MEDLINE Link]. [Full Text].
Young SD, Montes J, Kramer SS, Podwika B, Rao AK, De Vivo DC. Perceived Fatigue in Spinal Muscular Atrophy: A Pilot Study. J Neuromuscul Dis. 2018 Dec 14. [QxMD MEDLINE Link].
Puruckherr M, Mehta JB, Girish MR, et al. Severe obstructive sleep apnea in a patient with spinal muscle atrophy. Chest. 2004 Nov. 126(5):1705-7. [QxMD MEDLINE Link]. [Full Text].
Yasuma F, Kuru S, Konagaya M. Dilated cardiomyopathy in Kugelberg-Welander disease: coexisting sleep disordered breathing and its treatment with continuous positive airway pressure. Intern Med. 2004 Oct. 43(10):951-4. [QxMD MEDLINE Link]. [Full Text].
Swoboda KJ, Kissel JT, Crawford TO, et al. Perspectives on clinical trials in spinal muscular atrophy. J Child Neurol. 2007 Aug. 22(8):957-66. [QxMD MEDLINE Link].
US Food and Drug Administration. SPINRAZA (nusinersen) injection, for intrathecal use. FDA. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf. Revised December 2016; Accessed: November 17, 2020.
US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. FDA. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-spinal-muscular-atrophy. December 23, 2016; Accessed: November 17, 2020.
US Food and Drug Administration. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. FDA. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease. May 24, 2019; Accessed: November 17, 2020.
US Food and Drug Administration. FDA Approves Oral Treatment for Spinal Muscular Atrophy. FDA. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy. August 7, 2020; Accessed: November 17, 2020.
Il'ina NA, Antipova RI, Khokhlov AP. [Use of lithium carbonate to treat Kugelberg--Welander spinal amyotrophy]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1980. 80(11):1657-60. [QxMD MEDLINE Link].
Tzeng AC, Cheng J, Fryczynski H, et al. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil. 2000 Sep-Oct. 79(5):435-40. [QxMD MEDLINE Link].
Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol. 2003 Aug. 18(8):537-41. [QxMD MEDLINE Link].

Media Gallery

of 0

Author

Joyce L Oleszek, MD Professor, Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine; Co-Director, Rhizotomy Program, Children’s Hospital Colorado

Joyce L Oleszek, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Coauthor(s)

Stephanie E Vallee, MS Certified Genetic Counselor, Dartmouth-Hitchcock Medical Center, Children's Hospital at Dartmouth

Disclosure: Nothing to disclose.

Michael Dichiaro, MD Senior Instructor, Pediatric Rehabilitation Medicine, Children's Hospital Colorado

Michael Dichiaro, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists, American Academy of Cerebral Palsy and Developmental Medicine

Disclosure: Nothing to disclose.

Mary Louise Caire, MD Consulting Staff, Department of Physical Medicine and Rehabilitation, Wise Regional Medical Center

Mary Louise Caire, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, Texas Medical Association, American Medical Association

Disclosure: Nothing to disclose.

Stephen Kishner, MD, MHA Clinical Professor, Louisiana State University School of Medicine in New Orleans

Stephen Kishner, MD, MHA is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kat Kolaski, MD Assistant Professor, Departments of Orthopedic Surgery and Pediatrics, Wake Forest University School of Medicine

Kat Kolaski, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Chief Editor

Additional Contributors

Teresa L Massagli, MD Professor of Rehabilitation Medicine, Adjunct Professor of Pediatrics, University of Washington School of Medicine

Teresa L Massagli, MD is a member of the following medical societies: Academy of Spinal Cord Injury Professionals, American Academy of Physical Medicine and Rehabilitation, Association of Academic Physiatrists

Disclosure: Nothing to disclose.

Sections Kugelberg Welander Spinal Muscular Atrophy
Overview
Presentation
- History
- Physical
- Causes
- Show All
DDx
Workup
Treatment
Medication
Follow-up
Questions & Answers
References

Kugelberg Welander Spinal Muscular Atrophy Workup

Laboratory Studies

Imaging Studies

Other Tests

References

Tables

Contributor Information and Disclosures

What would you like to print?